HNHA

HNHA is a potent HDAC inhibitor with an IC50 of 100 nM. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer[1].

Product Specifications

CAS Number

[926908-04-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HDAC; HIF/HIF Prolyl-Hydroxylase; MMP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hnha.html

Purity

99.76

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NO)CCCCCCSC1=CC=C2C=CC=CC2=C1

Molecular Formula

C17H21NO2S

Molecular Weight

303.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Park KC, et al. Potential anti-cancer activity of N-hydroxy-7- (2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. Cancer Sci. 2011 Feb;102 (2) :343-50.